Generic Name and Formulations:
Tolterodine tartrate 1mg, 2mg; tabs.
Indications for DETROL:
Overactive bladder with symptoms of urinary frequency, urgency, or urge incontinence.
2mg twice daily; may decrease to 1mg twice daily. Concomitant strong CYP3A4 inhibitors (ketoconazole, itraconazole, miconazole, clarithromycin, erythromycin, cyclosporine, vinblastine), or significant renal or hepatic dysfunction: 1mg twice daily.
Urinary or gastric retention. Uncontrolled narrow-angle glaucoma. Fesoterodine fumarate allergy.
Bladder outflow obstruction. GI obstruction (eg, pyloric stenosis). Decreased GI motility. Discontinue if angioedema occurs. Monitor for anticholinergic CNS effects (esp. when starting treatment and after dose increases). Narrow-angle glaucoma. Myasthenia gravis. History of QT prolongation. Pregnancy. Nursing mothers: not recommended.
Plasma levels increased by CYP3A4 inhibitors (see Adult dose). Caution with Class IA (eg, quinidine, procainamide) or Class III (eg, amiodarone, sotalol) antiarrhythmics. Additive anticholinergic effects with other anticholinergics.
Dry mouth/eyes, headache, constipation, abdominal pain, dyspepsia, fatigue, dizziness, somnolence, sinusitis, abnormal vision, anxiety, dysuria, other anticholinergic effects; anaphylaxis, angioedema.
Hepatic (CYP2D6, 3A4).
Renal (primarily), fecal.
LA—30, 90, 500; Tabs—60, 500
Neurology Advisor Articles
- Some Statins May Be Associated With Cognition, Memory Deficits
- Neuropathic Pain Treatments
- Cannabis for Multiple Sclerosis: Prescriber's Perspective
- New Monoclonal Antibody BAN2401 Reduces Amyloid Plaques, Improves Cognition in Alzheimer's
- Nonpharmacologic Interventions for Alzheimer's Have Greater Impact on Outcomes Than Currently Available Medications
- OnabotulinumtoxinA for Post-Stroke Spasticity: Treatment Strategies and Limitations
- Tau Associated With Loss of Anterior Temporal White Matter Integrity
- Location Probability Learning Unimpaired in Parkinson Disease
- Prenatal Tdap Vaccination Not Linked to Autism Risk
- AMA Adopts Policy to Advance Gender Equity in Medicine